Table 2.

Association between statin use and odds of Crohn’s disease.

Statin use status	Cases/ controls [n]	Basic modela OR [95% CI]	p-value	Full modelb OR [95% CI]	p-value
No statin use	7017/69949	Referent		Referent
Any statin use	620 /6421	0.95 [0.87–1.05]	0.34	0.71 [0.63–0.79]	<0.001
Current statin usec	519/5642	0.90 [0.81–1.00]	0.039	0.67 [0.60–0.75]	<0.001
Cumulative statin dose, DDDd
31–325	138/1476	0.93 [0.77–1.11]	0.41	0.73 [0.61–0.88]	0.001
326–750	169/1616	1.04 [0.88–1.22]	0.68	0.78 [0.66–0.93]	0.005
751–1500	151/1680	0.89 [0.75–1.06]	0.18	0.64 [0.53–0.77]	<0.001
>1500	162/1649	0.97 [0.81–1.15]	0.72	0.66 [0.55–0.80]	<0.001
Ptrend e		0.56		0.10

NSAID, non-steroidal anti-inflammatory drug.

^aThe basic model controlled for the matching factors sex, age, and area or residence through conditional logistic regression.

^bThe full model was a conditional logistic model additionally adjusted for education, previous use of NSAIDs or oral contraceptives, and previous history of hypertension, ischaemic heart disease, stroke, other arterial diseases, heart failure, and type 1 and type 2 diabetes.

^cCurrent use required a dispensed statin prescription in the 12 months preceding diagnosis/indexing.

^dCumulative dose among those with any statin use in WHO Defined Daily Dose [DDD].

^e p for linear trend was calculated for statin users only, using the continuous variable for cumulative DDD.